Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

180 Life Sciences Corp

Healthcare US ATNF

NoneUSD
0.00(0%)

Last update at 2025-11-20T20:07:16.315690Z

Day Range

--
LowHigh

52 Week Range

1.168.00
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap4.29M
  • VolumeNone
  • P/E Ratio0.27
  • Dividend Yield-%
  • EBITDA-8.82697M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM7.98

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -39.66901M -10.90448M -10.90448M -25.40354M -0.01450M
Minority interest - - - - -
Net income -38.72626M -10.88406M -10.88406M -25.39405M -0.01450M
Selling general administrative 15.47M 3.36M 3.36M 18.85M 0.00767M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.11M 0.11M 0.13M 0.07M -
Ebit -17.89796M -9.81751M -5.38337M -20.86329M -0.00870M
Ebitda -17.78896M -9.69218M -5.25804M -20.56286M -0.00872M
Depreciation and amortization 0.11M 0.13M 0.13M 0.30M -0.00002M
Non operating income net other - - - - -
Operating income -17.89796M -5.64811M -5.64811M -20.86329M -0.00874M
Other operating expenses 17.90M 5.65M 5.65M 20.89M 0.01M
Interest expense 0.03M 1.09M 1.09M 0.19M 0.00000M
Tax provision -0.94275M -0.02320M -0.02043M 0.26M 0.41M
Interest income - - 0.00000M 1.37M 2.05M
Net interest income -0.02667M -0.18621M -1.08697M -0.18141M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.94275M -0.02043M -0.02043M -0.00950M 0.00005M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 17.90M 5.65M 5.65M 20.89M -0.01451M
Cost of revenue - - - - -
Total other income expense net -21.77104M -5.25637M -4.16940M -4.54026M -0.00575M
Discontinued operations - - - - -
Net income from continuing ops -38.72626M -20.32465M -10.88406M -25.39405M -
Net income applicable to common shares - -20.32465M -12.00676M -25.39405M -14.49544M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5.26M 19.65M 55.53M 55.53M 51.88M
Intangible assets 1.62M 10.72M 14.62M 14.62M 14.66M
Earning assets - - - - -
Other current assets 1.39M 1.96M 0.01M 0.01M 0.03M
Total liab 5.39M 8.31M 25.25M 25.25M 13.31M
Total stockholder equity -0.12773M 11.34M 30.29M 30.29M 38.57M
Deferred long term liab - - 12.58M 12.57M 12.54M
Other current liab 1892612.87M 2.55M 4.44M 4.44M 2.01M
Common stock 0.00005M 0.00038M 0.00262M 0.00262M 0.00138M
Capital stock 0.00005M 0.00038M 0.00340M 0.00262M 0.00138M
Retained earnings -127.34366M -107.40855M -48.35764M -48.35764M -37.47358M
Other liab - - 3.64M 3.71M 3.67M
Good will - 0.00000M 36.90M 36.90M 36.42M
Other assets - - 15.55M 12.57M 12.54M
Cash 1.98M 6.97M 2.11M 2.11M 0.08M
Cash and equivalents - - - - -
Total current liabilities 5.06M 5.66M 21.42M 21.42M 9.64M
Current deferred revenue -1892611.00000M - 4.78M - -
Net debt -0.65573M -5.63040M 1.67M 1.67M 3.44M
Short term debt 1.30M 1.31M 3.67M 3.67M 3.53M
Short long term debt 1.03M 1.31M 1.91M 3.67M 3.53M
Short long term debt total 1.32M 1.34M 3.78M 3.78M 3.53M
Other stockholder equity 130.12M 121.64M 78.01M 0.64M 75.89M
Property plant equipment - - - - 0.05M
Total current assets 3.64M 8.93M 4.01M 4.01M 0.75M
Long term investments - - - - -
Net tangible assets - - 0.39M -8.66175M 0.03M
Short term investments - - - - 11.88M
Net receivables 0.28M 0.62M 0.78M 0.78M 0.33M
Long term debt 0.02M 0.03M 0.05M 0.11M -
Inventory - -0.62097M 1.11M - 0.30M
Accounts payable 1.89M 1.80M 8.53M 8.53M 4.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.90134M -2.88552M 0.64M 0.64M 0.15M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00262M 0.00138M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M 9.06M - - -
Deferred long term asset charges - - - - -
Non current assets total 1.62M 10.72M 51.52M 51.52M 51.14M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - 0.00000M 14.49M -0.70815M -
Change to liabilities - -5.73054M 2.23M 2.37M 0.31M
Total cashflows from investing activities - - 14.49M -0.70815M -0.09083M
Net borrowings - 0.80M 0.20M 2.69M 2.69M
Total cash from financing activities 10.87M -8.73393M -8.73393M 3.94M 0.16M
Change to operating activities - -3.07640M 0.11M 0.67M -0.11752M
Net income -38.72626M -10.88406M -10.88406M -25.39405M 1.04M
Change in cash -1.25440M 2.03M -8.73393M -0.48382M -0.15751M
Begin period cash flow 8.22M 0.08M 0.08M 0.57M 0.43M
End period cash flow 6.97M 2.11M 2.11M 0.08M 0.27M
Total cash from operating activities -12.12758M -3.87196M -3.87196M -3.31865M -0.78923M
Issuance of capital stock 12.50M 26.67M 0.07M 1.13M -
Depreciation 0.11M 0.13M 0.13M 0.07M 0.02M
Other cashflows from investing activities - - 11.48M -0.64982M -0.64982M
Dividends paid - -0.47477M - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -1.01497M -9.00649M -9.00649M -108.42735M -
Other cashflows from financing activities 1.06M 0.75M -0.20186M 2.81M 0.16M
Change to netincome - 9.65M 4.20M 18.97M 10.36M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.14M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.72M 2.33M 2.33M 3.04M 0.07M
Stock based compensation 2.63M 1.12M 1.12M 13.30M -
Other non cash items 22.08M 3.46M 0.72M 5.68M -1.89995M
Free cash flow -12.12758M -3.87196M -3.87196M -3.46306M -0.78923M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ATNF
180 Life Sciences Corp		 - -% - 0.27 6.08 - 1.11 -0.4596
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.

180 Life Sciences Corp

Building 4, Palo Alto, CA, United States, 94306

Key Executives

Name Title Year Born
Dr. James N. Woody M.D., Ph.D. CEO & Director 1942
Mr. Ozan Pamir C.F.A. Interim CFO & Sec. 1992
Mr. Quan Anh Vu COO & Chief Bus. Officer 1972
Dr. Jonathan B. Rothbard Ph.D. Chief Scientific Officer 1952
Dr. Raphael Mechoulam Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Mr. Jason Assad Director of IR NA
Prof. Jagdeep Nanchahal Chief Medical Officer & Chairman of Clinical Advisory Board NA
Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder & Executive Chairman 1948
Mr. Ozan Pamir C.F.A. CFO & Secretary 1992
Dr. Jonathan B. Rothbard Ph.D. Chief Scientific Officer 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions